Marcello Mario Mascia
Marcello Mario Mascia has a total of 284 co-authors. Here are the top co-authors by number of shared publications:
Giovanni Defazio
Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Piazza Giulio Cesare 11, Bari, 70124, Italy
15 shared publications- Vittorio Velucci
Department of Translational Biomedicine and Neuroscience University of Bari Aldo Moro Bari Italy
8 shared publications - Angelo Fabio Gigante
Section of Neurology, San Paolo Hospital Bari Italy
7 shared publications Giovanni Cossu
Department of Neuroscience, Neurology Service and Stroke Unit, AO Brotzu, Cagliari, Italy
7 shared publicationsRoberta Pellicciari
Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy
7 shared publications- Tommaso Ercoli
Department of Neurology, University of Sassari, Viale S. Pietro 10, 07100 Sassari, Italy
7 shared publications
Latest Publications
- Open Access
- 4 October 2026
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (4) , 885-889
Ekbom Spectrum Psychosis Associated with 24-hour Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in Parkinson’s Disease
Mario Meloni, Fabrizio De Ascaniis, Gianni Orofino, Massimo Marano, Martina Mulas, Monica Puligheddu, Marcello Mario Mascia. Clin Psychopharmacol Neurosci 2026;24:885-9. https://doi.org/10.9758/cpn.26.1449
- 4 October 2026
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (4) , 885-889
Open AccessEkbom Spectrum Psychosis Associated with 24-hour Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in Parkinson’s Disease
Mario Meloni, Fabrizio De Ascaniis, Gianni Orofino, Massimo Marano, Martina Mulas, Monica Puligheddu, Marcello Mario Mascia. Clin Psychopharmacol Neurosci 2026;24:885-9. https://doi.org/10.9758/cpn.26.1449
- 2 May 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (5)
Multicenter validation of the Italian Pain in Dystonia Scale in idiopathic adult-onset cervical dystonia
The Pain in Dystonia Scale (PIDS) is a self-administered instrument to assess pain in dystonia, validated in cervical dystonia (CD). To translate and culturally adapt the PIDS into Italian following a standardized forward-backward procedure and to validate the resulting Italian version (I-PIDS) in patients with idiopathic adult-onset CD as part of a multicenter effort aimed at evaluating its clinimetric properties across dystonia subtypes. I-PIDS was completed by 64 Italian patients with cervical dystonia from 16 centers, three months or more after their last botulinum toxin treatment. Standard clinimetric analyses were performed. Acceptability was optimal, with no missing data. Score distributions met expected criteria, with mean-median differences <10% of the maximum score for all body regions except the jaw, and no floor or ceiling effects. Internal consistency was satisfactory for all pain regions (α = 0.81-0.91) and for functional impact (α = 0.83) and modulating factors (α = 0.73-0.74). Convergent validity was demonstrated by a moderate correlation between neck pain scores and the Global Dystonia Rating Scale (r = 0.39, p = 0.03), while divergent validity was supported by the absence of correlation with the Montreal Cognitive Assessment (r = 0.02, p = 0.90). Exploratory analyses suggested that pain severity in CD was not associated with age, sex, education, age at onset, or dystonia duration, and that pain frequently involved multiple body regions, independently of dystonia distribution. These findings support the validity of I-PIDS and provide further insight into the pattern of pain in CD.
- 2 May 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (5)
Multicenter validation of the Italian Pain in Dystonia Scale in idiopathic adult-onset cervical dystonia
The Pain in Dystonia Scale (PIDS) is a self-administered instrument to assess pain in dystonia, validated in cervical dystonia (CD). To translate and culturally adapt the PIDS into Italian following a standardized forward-backward procedure and to validate the resulting Italian version (I-PIDS) in patients with idiopathic adult-onset CD as part of a multicenter effort aimed at evaluating its clinimetric properties across dystonia subtypes. I-PIDS was completed by 64 Italian patients with cervical dystonia from 16 centers, three months or more after their last botulinum toxin treatment. Standard clinimetric analyses were performed. Acceptability was optimal, with no missing data. Score distributions met expected criteria, with mean-median differences <10% of the maximum score for all body regions except the jaw, and no floor or ceiling effects. Internal consistency was satisfactory for all pain regions (α = 0.81-0.91) and for functional impact (α = 0.83) and modulating factors (α = 0.73-0.74). Convergent validity was demonstrated by a moderate correlation between neck pain scores and the Global Dystonia Rating Scale (r = 0.39, p = 0.03), while divergent validity was supported by the absence of correlation with the Montreal Cognitive Assessment (r = 0.02, p = 0.90). Exploratory analyses suggested that pain severity in CD was not associated with age, sex, education, age at onset, or dystonia duration, and that pain frequently involved multiple body regions, independently of dystonia distribution. These findings support the validity of I-PIDS and provide further insight into the pattern of pain in CD.
- Open Access
- 18 February 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (8) , 1933-1939
The Pain in Dystonia Scale (PIDS)—Validation in Craniofacial and Upper Limb Dystonia
Background: Pain is one of the most disabling non‐motor symptoms in adult‐onset isolated dystonia (AOID). The Pain in Dystonia Scale (PIDS) was developed and validated in cervical dystonia. Its applicability to other focal subtypes remains unknown. Objectives: To validate the PIDS in patients with craniofacial and upper limb dystonia, expanding its use beyond cervical dystonia. Methods: We conducted a two‐phase cross‐sectional validation study in independent cohorts from Calgary, Canada and Italy. The Calgary pilot cohort ( n = 20) included participants with craniofacial and/or upper limb dystonia who completed the PIDS twice for test–retest reliability and a battery of comparator scales. The Italian cohort ( n = 109) was recruited through the Italian Dystonia Registry and completed the PIDS after cross‐cultural adaptation. Internal consistency, test–retest reliability, construct validity, and distribution properties were assessed using established psychometric standards. Results: Pain was highly prevalent (90.0% Calgary; 96.3% Italy), with anatomical distribution varying by dystonia subtype. Internal consistency was high across both cohorts (Cronbach's alpha 0.82–0.96), with minimal floor and ceiling effects. Test–retest reliability in the pilot cohort was excellent (ICC = 0.85). Construct validity was supported by strong correlations between PIDS scores and established pain and quality‐of‐life measures. Functional impact and pain modulators were consistently reported across cohorts, with stress identified as the most frequent aggravating factor and rest and stretching as common relieving factors. Conclusions: The PIDS demonstrates reliability, validity, and feasibility in craniofacial and upper limb dystonia, supporting its adoption for evaluating dystonia‐related pain in clinical and research settings across the main focal subtypes.
- 18 February 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (8) , 1933-1939
Open AccessThe Pain in Dystonia Scale (PIDS)—Validation in Craniofacial and Upper Limb Dystonia
Background: Pain is one of the most disabling non‐motor symptoms in adult‐onset isolated dystonia (AOID). The Pain in Dystonia Scale (PIDS) was developed and validated in cervical dystonia. Its applicability to other focal subtypes remains unknown. Objectives: To validate the PIDS in patients with craniofacial and upper limb dystonia, expanding its use beyond cervical dystonia. Methods: We conducted a two‐phase cross‐sectional validation study in independent cohorts from Calgary, Canada and Italy. The Calgary pilot cohort ( n = 20) included participants with craniofacial and/or upper limb dystonia who completed the PIDS twice for test–retest reliability and a battery of comparator scales. The Italian cohort ( n = 109) was recruited through the Italian Dystonia Registry and completed the PIDS after cross‐cultural adaptation. Internal consistency, test–retest reliability, construct validity, and distribution properties were assessed using established psychometric standards. Results: Pain was highly prevalent (90.0% Calgary; 96.3% Italy), with anatomical distribution varying by dystonia subtype. Internal consistency was high across both cohorts (Cronbach's alpha 0.82–0.96), with minimal floor and ceiling effects. Test–retest reliability in the pilot cohort was excellent (ICC = 0.85). Construct validity was supported by strong correlations between PIDS scores and established pain and quality‐of‐life measures. Functional impact and pain modulators were consistently reported across cohorts, with stress identified as the most frequent aggravating factor and rest and stretching as common relieving factors. Conclusions: The PIDS demonstrates reliability, validity, and feasibility in craniofacial and upper limb dystonia, supporting its adoption for evaluating dystonia‐related pain in clinical and research settings across the main focal subtypes.
- 21 November 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (5) , 1277-1282
Titration Dynamics and Early Treatment Burden in Advanced Parkinson's Disease: A Multicenter Comparison of CSFLI and LCIG Infusion Therapies
Background: Continuous subcutaneous infusion of foslevodopa/foscarbidopa (CSFLI) and intrajejunal levodopa‐carbidopa intestinal gel (LCIG) are established options for advanced Parkinson's disease (PD). Real‐world data on early titration and management are limited. Objectives: To compare clinical course, safety, and practical implications of titration with CSFLI versus LCIG. Methods: In this retrospective study across nine Italian centers using uniform titration protocols, we analyzed 103 patients treated with CSFLI and 129 with LCIG. Clinical outcomes, levodopa equivalent daily dose (LEDD), follow‐up needs, and adverse events were evaluated over 3 months. Results: Both therapies improved motor symptoms and quality of life. CSFLI required more frequent follow‐up visits and larger LEDD increases to reach optimization, with common but generally mild local reactions. LCIG showed fewer titration demands, with occasional peristomal issues. Conclusions: While equally effective, CSFLI requires closer supervision during early management. Recognizing these practical differences can guide therapy selection and service planning in advanced PD.
- 21 November 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (5) , 1277-1282
Titration Dynamics and Early Treatment Burden in Advanced Parkinson's Disease: A Multicenter Comparison of CSFLI and LCIG Infusion Therapies
Background: Continuous subcutaneous infusion of foslevodopa/foscarbidopa (CSFLI) and intrajejunal levodopa‐carbidopa intestinal gel (LCIG) are established options for advanced Parkinson's disease (PD). Real‐world data on early titration and management are limited. Objectives: To compare clinical course, safety, and practical implications of titration with CSFLI versus LCIG. Methods: In this retrospective study across nine Italian centers using uniform titration protocols, we analyzed 103 patients treated with CSFLI and 129 with LCIG. Clinical outcomes, levodopa equivalent daily dose (LEDD), follow‐up needs, and adverse events were evaluated over 3 months. Results: Both therapies improved motor symptoms and quality of life. CSFLI required more frequent follow‐up visits and larger LEDD increases to reach optimization, with common but generally mild local reactions. LCIG showed fewer titration demands, with occasional peristomal issues. Conclusions: While equally effective, CSFLI requires closer supervision during early management. Recognizing these practical differences can guide therapy selection and service planning in advanced PD.
- Open Access
- 28 October 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (1) , 136-145
The impact of diet on Parkinson's disease risk: A data-driven analysis in a large Italian case-control population
Background: The role of dietary factors as risk or protective factors for Parkinson's disease (PD) remains debated. Objective: This retrospective case-control study aimed to evaluate the associations between foods identified through a data-driven analysis and PD, and to compare the relevance of dietary versus non-dietary factors as contributors to PD risk. Methods: The study included 680 PD patients and 612 matched controls recruited from six Italian neurology centers. Dietary data were collected using a validated 77-item food frequency questionnaire, and factor analysis was conducted to identify groups of correlated foods (i.e., factors). Logistic regression models were used to assess the associations between these factors and PD, while non-dietary factors were subsequently included in the model for comparison. Results: Seven factors were identified, four of which were significantly associated with PD. High consumption of sweets (Factor 1), red meat (Factor 3), and processed meats (Factor 6) was associated with an increased PD risk, whereas a high fruit intake (Factor 2) was protective. These associations remained significant after adjusting for other known non-dietary risk/protective factors. While the increased PD risk associated with dietary factors was weaker than that of non-dietary factors, protective dietary and non-dietary factors showed comparable effects in reducing PD risk. Conclusions: Data-driven analysis identified foods potentially influencing PD risk, although non-dietary factors demonstrated a greater impact on PD risk. These findings highlight the need to integrate both diet and lifestyle habits into future PD research and prevention strategies.
- 28 October 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (1) , 136-145
Open AccessThe impact of diet on Parkinson's disease risk: A data-driven analysis in a large Italian case-control population
Background: The role of dietary factors as risk or protective factors for Parkinson's disease (PD) remains debated. Objective: This retrospective case-control study aimed to evaluate the associations between foods identified through a data-driven analysis and PD, and to compare the relevance of dietary versus non-dietary factors as contributors to PD risk. Methods: The study included 680 PD patients and 612 matched controls recruited from six Italian neurology centers. Dietary data were collected using a validated 77-item food frequency questionnaire, and factor analysis was conducted to identify groups of correlated foods (i.e., factors). Logistic regression models were used to assess the associations between these factors and PD, while non-dietary factors were subsequently included in the model for comparison. Results: Seven factors were identified, four of which were significantly associated with PD. High consumption of sweets (Factor 1), red meat (Factor 3), and processed meats (Factor 6) was associated with an increased PD risk, whereas a high fruit intake (Factor 2) was protective. These associations remained significant after adjusting for other known non-dietary risk/protective factors. While the increased PD risk associated with dietary factors was weaker than that of non-dietary factors, protective dietary and non-dietary factors showed comparable effects in reducing PD risk. Conclusions: Data-driven analysis identified foods potentially influencing PD risk, although non-dietary factors demonstrated a greater impact on PD risk. These findings highlight the need to integrate both diet and lifestyle habits into future PD research and prevention strategies.
- Open Access
- 11 October 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (3) , 748-756
Segmental and Multifocal Isolated Dystonias: Similarities and Differences
Background: Whether the traditional distinction between segmental and multifocal dystonia is clinically or scientifically useful remains unclear. Objective: To evaluate whether idiopathic isolated adult‐onset segmental and multifocal dystonia can be differentiated based on clinical features other than the contiguity of affected body regions. Methods: We compared data on segmental and multifocal dystonia from two large dystonia databases established in the USA and Italy that used similar criteria for patient recruitment and assessment. Results: Compared to segmental dystonia, multifocal dystonia was characterized by a higher proportion of men, a younger age at dystonia onset, a greater frequency of upper limb dystonia, and a lower frequency of cranial dystonia at both onset and last examination. Segmental and multifocal dystonia had a similar frequency of alleviating maneuvers, non‐motor eye symptoms in blepharospasm, and neck pain and tremor in cervical dystonia. Although the initial spread pattern from focal to segmental or multifocal appeared faster in the segmental dystonia group, adjusting the analysis for the initial body site involved revealed no significant differences between the two groups. Segmental and multifocal dystonia starting in the same body site showed similar age, sex, and spread characteristics. The observed differences and similarities were consistent across both independent databases. Conclusions: Segmental and multifocal dystonia share differences and similarities. The observed differences may reflect a difference in the predominant site of dystonia onset. From a clinical perspective, therefore, the segmental/multifocal distinction is probably not valuable in the dystonia classification scheme, although further data may be needed from a pathophysiological perspective.
- 11 October 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (3) , 748-756
Open AccessSegmental and Multifocal Isolated Dystonias: Similarities and Differences
Background: Whether the traditional distinction between segmental and multifocal dystonia is clinically or scientifically useful remains unclear. Objective: To evaluate whether idiopathic isolated adult‐onset segmental and multifocal dystonia can be differentiated based on clinical features other than the contiguity of affected body regions. Methods: We compared data on segmental and multifocal dystonia from two large dystonia databases established in the USA and Italy that used similar criteria for patient recruitment and assessment. Results: Compared to segmental dystonia, multifocal dystonia was characterized by a higher proportion of men, a younger age at dystonia onset, a greater frequency of upper limb dystonia, and a lower frequency of cranial dystonia at both onset and last examination. Segmental and multifocal dystonia had a similar frequency of alleviating maneuvers, non‐motor eye symptoms in blepharospasm, and neck pain and tremor in cervical dystonia. Although the initial spread pattern from focal to segmental or multifocal appeared faster in the segmental dystonia group, adjusting the analysis for the initial body site involved revealed no significant differences between the two groups. Segmental and multifocal dystonia starting in the same body site showed similar age, sex, and spread characteristics. The observed differences and similarities were consistent across both independent databases. Conclusions: Segmental and multifocal dystonia share differences and similarities. The observed differences may reflect a difference in the predominant site of dystonia onset. From a clinical perspective, therefore, the segmental/multifocal distinction is probably not valuable in the dystonia classification scheme, although further data may be needed from a pathophysiological perspective.
- 6 August 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 140, 107982
Non-motor symptom subtypes in early Parkinson's disease
- 6 August 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 140, 107982
Non-motor symptom subtypes in early Parkinson's disease
- Open Access
- 15 July 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (7) , e70179
Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa–Carbidopa Intestinal Gel: A Nation‐Wide, Multicenter, Longitudinal, “Real‐World” Study. The EPIC Study
Background: The outcome of levodopa/carbidopa intestinal gel (LCIG) in Parkinson's disease carriers of GBA1 mutations (GBA‐PD) remains uncertain.Objective: To evaluate the safety and efficacy of LCIG in a large PD cohort, focusing on GBA1 variants.Methods: This multicenter, retrospective, longitudinal “real‐world” study included consecutive patients with advanced PD treated with LCIG at 31 Italian centers; data were collected at baseline, 1‐, 5‐year, and last‐available follow‐up.Results: Data from 512 PD patients (59% male, mean age and disease duration at LCIG initiation 67.0 ± 8.0 and 12.9 ± 5.0 years, respectively) were analyzed. GBA1 genotyping was available for 306 patients (60%), of whom 40 (13%) had GBA1 mutations or risk variants. Mean follow‐up on LCIG was 3.9 ± 2.9 years; 5‐year follow‐up data were available for 159 subjects. At baseline, GBA‐PD had a younger age, shorter PD duration, worse cognition, and more hallucinations than noncarriers. At 1‐ and 5‐year follow‐up, LCIG improved motor and non‐motor symptoms, OFF‐time, and dyskinesias in the entire population. In GBA‐PD, MDS‐UPDRS parts I, II, and III scores did not change, while part IV score improved significantly less than in noncarriers; cognition and orthostatic hypotension symptoms worsened more rapidly. Multivariate analysis of predictors for adverse events and LCIG discontinuation found no significant contribution from GBA1 mutation status.Conclusions: GBA1 status does not increase the risk of adverse events or LCIG discontinuation. LCIG is a safe option for advanced GBA‐PD, even in patients with cognitive impairment at baseline. However, GBA‐PD experiences lower efficacy on motor disability and complications and faster cognitive decline than noncarriers.
- 15 July 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (7) , e70179
Open AccessEffects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa–Carbidopa Intestinal Gel: A Nation‐Wide, Multicenter, Longitudinal, “Real‐World” Study. The EPIC Study
Background: The outcome of levodopa/carbidopa intestinal gel (LCIG) in Parkinson's disease carriers of GBA1 mutations (GBA‐PD) remains uncertain.Objective: To evaluate the safety and efficacy of LCIG in a large PD cohort, focusing on GBA1 variants.Methods: This multicenter, retrospective, longitudinal “real‐world” study included consecutive patients with advanced PD treated with LCIG at 31 Italian centers; data were collected at baseline, 1‐, 5‐year, and last‐available follow‐up.Results: Data from 512 PD patients (59% male, mean age and disease duration at LCIG initiation 67.0 ± 8.0 and 12.9 ± 5.0 years, respectively) were analyzed. GBA1 genotyping was available for 306 patients (60%), of whom 40 (13%) had GBA1 mutations or risk variants. Mean follow‐up on LCIG was 3.9 ± 2.9 years; 5‐year follow‐up data were available for 159 subjects. At baseline, GBA‐PD had a younger age, shorter PD duration, worse cognition, and more hallucinations than noncarriers. At 1‐ and 5‐year follow‐up, LCIG improved motor and non‐motor symptoms, OFF‐time, and dyskinesias in the entire population. In GBA‐PD, MDS‐UPDRS parts I, II, and III scores did not change, while part IV score improved significantly less than in noncarriers; cognition and orthostatic hypotension symptoms worsened more rapidly. Multivariate analysis of predictors for adverse events and LCIG discontinuation found no significant contribution from GBA1 mutation status.Conclusions: GBA1 status does not increase the risk of adverse events or LCIG discontinuation. LCIG is a safe option for advanced GBA‐PD, even in patients with cognitive impairment at baseline. However, GBA‐PD experiences lower efficacy on motor disability and complications and faster cognitive decline than noncarriers.
- 20 June 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (10) , 5111-5121
The relationship between occupation and specific forms of idiopathic adult-onset dystonia
Background The development of idiopathic adult-onset dystonia (IAOD) in different body parts is associated with specific demographic and clinical characteristics, as well as with specific risk factors. Objective To investigate whether specific occupations are associated with specific forms of IAOD at onset, namely blepharospasm (BSP), cervical dystonia (CD), and task-specific upper limb dystonia (TS-ULD). Methods Data from 905 IAOD patients enrolled in the Italian Dystonia Registry were analysed. Each patient was assigned to the corresponding occupational category by specialists in occupational medicine according to the classification of the Italian National Institute of Statistics. Logistic regression models (adjusted for sex, year of birth, Italian geographical areas, and age at dystonia onset) were computed to assess the association between occupation and specific dystonia at onset, using patients who developed focal dystonia in other body parts as controls. Results Compared to other occupations, trades workers exhibited an increased risk for BSP at onset (OR = 2.6, 95% CI 1.6–4.2), cleaners for CD (OR = 3.4, 95% CI 1.2–9.9), and musicians for TS-ULD (OR = 36.3, 95% CI 11.3–117.1). The longer the duration of employment before the onset of dystonia, the greater the risk of dystonia. Conclusions We provided novel information indicating that exposure to specific occupations may trigger specific forms of IAOD, namely BSP, CD, and TS-ULD. The associations highlighted by this study may reflect a common pathophysiological mechanism relying on the frequent performance of repetitive movements in a specific body part.
- 20 June 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (10) , 5111-5121
The relationship between occupation and specific forms of idiopathic adult-onset dystonia
Background The development of idiopathic adult-onset dystonia (IAOD) in different body parts is associated with specific demographic and clinical characteristics, as well as with specific risk factors. Objective To investigate whether specific occupations are associated with specific forms of IAOD at onset, namely blepharospasm (BSP), cervical dystonia (CD), and task-specific upper limb dystonia (TS-ULD). Methods Data from 905 IAOD patients enrolled in the Italian Dystonia Registry were analysed. Each patient was assigned to the corresponding occupational category by specialists in occupational medicine according to the classification of the Italian National Institute of Statistics. Logistic regression models (adjusted for sex, year of birth, Italian geographical areas, and age at dystonia onset) were computed to assess the association between occupation and specific dystonia at onset, using patients who developed focal dystonia in other body parts as controls. Results Compared to other occupations, trades workers exhibited an increased risk for BSP at onset (OR = 2.6, 95% CI 1.6–4.2), cleaners for CD (OR = 3.4, 95% CI 1.2–9.9), and musicians for TS-ULD (OR = 36.3, 95% CI 11.3–117.1). The longer the duration of employment before the onset of dystonia, the greater the risk of dystonia. Conclusions We provided novel information indicating that exposure to specific occupations may trigger specific forms of IAOD, namely BSP, CD, and TS-ULD. The associations highlighted by this study may reflect a common pathophysiological mechanism relying on the frequent performance of repetitive movements in a specific body part.
- Open Access
- 9 April 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (5) , 1-8
The natural history of body-first versus brain-first Parkinson’s disease subtypes
Background: Several lines of evidence support the hypothesis of brain-first and body-first Parkinson’s disease (PD) subtypes, characterized by distinct origins of α-synuclein pathology. However, data on premotor non-motor burden and motor progression in these subtypes remain inconsistent. Objective: To analyze the natural history of body-first versus brain-first PD subtypes. Methods: Data from 400 PD patients enrolled at a single Italian center were analyzed. All patients underwent a standardized retrospective baseline assessment of premotor and motor symptoms at onset and were prospectively followed. Premotor REM sleep behavior disorder (RBD), considered a prodromal phenotype of the body-first subtype, was used to divide patients into two groups: 81 patients with probable premotor RBD (PDpreRBD+) and 319 patients without (PDpreRBD−). Results: At motor onset, PDpreRBD+ patients were older than PDpreRBD− patients, exhibited less tremor, and more frequently presented with bilateral motor symptoms. PDpreRBD+ patients also reported a greater burden of premotor symptoms, including hyposmia, cognitive impairment, pain, constipation, and other dysautonomic symptoms. Over the follow-up period, PDpreRBD+ patients progressed more rapidly to Hoehn and Yahr stage 3, even after adjusting for sex, years of schooling, age at motor onset, and initial motor phenotype. Conclusions: Our results align with the hypothesis of brain-first and body-first PD subtypes, providing novel insights into their different premotor non-motor burden and motor progression trajectories.
- 9 April 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (5) , 1-8
Open AccessThe natural history of body-first versus brain-first Parkinson’s disease subtypes
Background: Several lines of evidence support the hypothesis of brain-first and body-first Parkinson’s disease (PD) subtypes, characterized by distinct origins of α-synuclein pathology. However, data on premotor non-motor burden and motor progression in these subtypes remain inconsistent. Objective: To analyze the natural history of body-first versus brain-first PD subtypes. Methods: Data from 400 PD patients enrolled at a single Italian center were analyzed. All patients underwent a standardized retrospective baseline assessment of premotor and motor symptoms at onset and were prospectively followed. Premotor REM sleep behavior disorder (RBD), considered a prodromal phenotype of the body-first subtype, was used to divide patients into two groups: 81 patients with probable premotor RBD (PDpreRBD+) and 319 patients without (PDpreRBD−). Results: At motor onset, PDpreRBD+ patients were older than PDpreRBD− patients, exhibited less tremor, and more frequently presented with bilateral motor symptoms. PDpreRBD+ patients also reported a greater burden of premotor symptoms, including hyposmia, cognitive impairment, pain, constipation, and other dysautonomic symptoms. Over the follow-up period, PDpreRBD+ patients progressed more rapidly to Hoehn and Yahr stage 3, even after adjusting for sex, years of schooling, age at motor onset, and initial motor phenotype. Conclusions: Our results align with the hypothesis of brain-first and body-first PD subtypes, providing novel insights into their different premotor non-motor burden and motor progression trajectories.